Omalizumab (tradename Xolair, Genentech) is a recombinant human IgG monoclonal antibody direct against IgE. It is administered by subcutaneous injection to patients with persistent asthma who show an inadequate response to inhaled corticosteroids.
Patient selection: age >= 12 years of age
Parameters:
(1) serum IgE levels before therapy
(2) body weight
Frequency of Subcutaneous Injections
Body Weight in Kilograms
IgE in IU/mL
30 - 60 kg
60.1 - 70 kg
70.1 - 90 kg
90.1 - 150 kg
30 - 100
4 weeks
4 weeks
4 weeks
4 weeks
100.1 - 200
4 weeks
4 weeks
4 weeks
2 weeks
200.1 - 300
4 weeks
2 weeks
2 weeks
2 weeks
300.1 - 400
2 weeks
2 weeks
2 weeks
NA
400.1 - 500
2 weeks
2 weeks
2 weeks
NA
500.1 - 600
2 weeks
2 weeks
NA
NA
600.1 - 700
2 weeks
NA
NA
NA
Dose for Subcutaneous Injection in milligrams (increments of 75 mg)
Body Weight in Kilograms
IgE in IU/mL
30 - 60 kg
60.1 - 70 kg
70.1 - 90 kg
90.1 - 150 kg
30 - 100
150
150
150
300
100.1 - 200
300
300
300
225
200.1 - 300
300
225
225
300
300.1 - 400
225
225
300
NA
400.1 - 500
300
300
375
NA
500.1 - 600
300
375
NA
NA
600.1 - 700
375
NA
NA
NA
Dose in mg
Injections of 1.2 mL
(1 vial)
Injections of 0.6 mL
(0.5 vial)
150
1
0
225
1
1
300
2
0
375
2
1
To read more or access our algorithms and calculators, please log in or register.
